

Haematologica
HAEMATOL/2018/206987
Version 1

The stepchild in myeloma treatments: allogeneic transplantation not so bad after all?

Antonia M.S. Müller, Shaji K. Kumar, and Benedetto Bruno

Disclosures: Antonia Mueller - Advisory Boards: Celgene, KITE, Incyte Shaji Kumar - Research funding for clinical trials to the institution: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Consulting/Advisory Board participation: (with no personal payments) Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen (with personal payment) Oncopeptides, Adaptive. Honorarium: Dr. Reddys Lab, Ono Pharmaceuticals Benedetto Bruno - None

Contributions: AM wrote the manuscript SK and BB critically reviewed and edited the manuscript